Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SMTI logo SMTI
Upturn stock ratingUpturn stock rating
SMTI logo

Sanara Medtech Inc (SMTI)

Upturn stock ratingUpturn stock rating
$28.39
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: SMTI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $49

1 Year Target Price $49

Analysts Price Target For last 52 week
$49Target price
Low$25.86
Current$28.39
high$39.08

Analysis of Past Performance

Type Stock
Historic Profit -48.36%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 252.33M USD
Price to earnings Ratio -
1Y Target Price 49
Price to earnings Ratio -
1Y Target Price 49
Volume (30-day avg) 2
Beta 1.33
52 Weeks Range 25.86 - 39.08
Updated Date 07/1/2025
52 Weeks Range 25.86 - 39.08
Updated Date 07/1/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.34

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -12.48%
Operating Margin (TTM) -8.88%

Management Effectiveness

Return on Assets (TTM) -4.72%
Return on Equity (TTM) -29.22%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 275469435
Price to Sales(TTM) 2.76
Enterprise Value 275469435
Price to Sales(TTM) 2.76
Enterprise Value to Revenue 3.01
Enterprise Value to EBITDA -29.03
Shares Outstanding 8887850
Shares Floating 3593181
Shares Outstanding 8887850
Shares Floating 3593181
Percent Insiders 66.47
Percent Institutions 10.43

Analyst Ratings

Rating 1
Target Price 49
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Sanara Medtech Inc

stock logo

Company Overview

overview logo History and Background

Sanara Medtech Inc. (formerly Wound Management Technologies) focuses on developing, marketing, and distributing wound and skin care products. Founded in 2008. They've grown through product development and strategic acquisitions.

business area logo Core Business Areas

  • Wound and Skin Care: Develops, markets, and distributes wound and skin care products to physicians, hospitals, and patients.

leadership logo Leadership and Structure

Ron Nixon is the current CEO. The company has a typical corporate structure with departments for R&D, marketing, sales, and operations.

Top Products and Market Share

overview logo Key Offerings

  • CellerateRX Surgical Activated Collagen: An enzymatic collagen powder indicated for partial and full-thickness wounds, pressure ulcers, surgical wounds, and diabetic foot ulcers. Revenue figures are not publicly available. Competitors include Integra LifeSciences and ACell, Inc. Market share is not publicly available.
  • BIAKOSTM Antimicrobial Skin and Wound Cleanser: This product is a broad-spectrum antimicrobial solution that helps prevent infections in wounds and skin injuries. Revenue figures are not publicly available. Competitors include Mylan and other manufacturers of antimicrobial solutions. Market share is not publicly available.

Market Dynamics

industry overview logo Industry Overview

The wound care market is growing, driven by an aging population, increasing rates of diabetes and obesity, and advancements in wound care technologies.

Positioning

Sanara Medtech focuses on advanced wound care solutions, particularly collagen-based products. It aims to differentiate itself through innovative technology and clinical efficacy.

Total Addressable Market (TAM)

The global wound care market is estimated to be in the billions of dollars. Sanara Medtech is positioned to capture a portion of this TAM through its specialized products and targeted market approach.

Upturn SWOT Analysis

Strengths

  • Proprietary collagen technology
  • Focus on high-growth wound care market
  • Strategic acquisitions to expand product portfolio

Weaknesses

  • Smaller market capitalization compared to major competitors
  • Limited financial resources for extensive marketing
  • Dependence on key product lines

Opportunities

  • Expansion into new geographic markets
  • Development of new wound care products
  • Strategic partnerships with larger healthcare companies

Threats

  • Competition from larger, well-established companies
  • Pricing pressures in the healthcare market
  • Regulatory changes affecting wound care products

Competitors and Market Share

competitor logo Key Competitors

  • ITCI
  • BSX
  • ABMD
  • HSDT
  • MRKR

Competitive Landscape

Sanara Medtech competes with larger companies in the wound care market. Its advantages lie in its specialized products and technology, while its disadvantages include limited resources and market reach.

Major Acquisitions

Medical Products Laboratories, Inc.

  • Year: 2018
  • Acquisition Price (USD millions): 17.5
  • Strategic Rationale: Expanded Sanara's product portfolio and manufacturing capabilities.

Growth Trajectory and Initiatives

Historical Growth: Sanara Medtech has grown organically and through acquisitions. Historical growth has been variable. Growth will depend on the market conditions of the stock

Future Projections: Future growth projections will depend on the market conditions of the stock and analyst consensus will depend on recent news. Consult financial news outlets for projections.

Recent Initiatives: Recent initiatives could include new product launches, strategic acquisitions, and partnerships.

Summary

Sanara Medtech is a small cap company focused on the growing wound care market. Its proprietary collagen technology and strategic acquisitions position it for growth. However, it faces competition from larger players and needs to manage its resources effectively. Recent financial performance and pipeline advancements are key indicators of future potential. Strong pipeline growth is what the company needs to look out for.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Company Investor Relations
  • Market Research Reports
  • Financial News Outlets

Disclaimers:

This analysis is based on available information and is not financial advice. Market conditions and company performance can change rapidly.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Sanara Medtech Inc

Exchange NASDAQ
Headquaters Fort Worth, TX, United States
IPO Launch date 2011-02-22
Executive Chairman & CEO Mr. Ronald T. Nixon
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 141
Full time employees 141

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.